Lotte Biologics said Wednesday it has signed a manufacturing agreement with multinational biotechnology company Alvotech as the Korean contract development and manufacturing organization continues to expand its global partnerships.
Under the agreement, which was signed on the sidelines of CPHI Milan 2026 taking place in Italy from Tuesday to Thursday, Lotte Biologics will manufacture multiple antibody biosimilar drug substances developed by Alvotech at its facility in Syracuse, New York, for supply to global markets. The two companies plan to expand their collaboration further in the future, according to Lotte Biologics.
“Alvotech’s expertise in biosimilar development, combined with Lotte Biologics’ manufacturing capabilities, creates a strong foundation for this collaboration,” James Park, co-CEO of Lotte Biologics, said.
“We look forward to strategically supporting Alvotech’s growing portfolio and the reliable supply of high-quality, more affordable biologic medicines to patients worldwide. With our Syracuse operations and the completion of our Songdo Bio Campus, we are committed to providing flexible, dual-site manufacturing support as the partnership grows.”
Lotte Biologics' Syracuse site features 40,000 liters of bioreactor capacity for biopharmaceutical manufacturing along with in-house process development and quality control capabilities.
According to Lotte, the facility recently passed an unannounced inspection by the US Food and Drug Administration with zero observations, demonstrating its compliance with global quality and regulatory standards.
The additional capacity secured through Lotte Biologics is expected to complement Alvotech’s in-house development and manufacturing capabilities and existing partnerships, supporting its expanding product portfolio and enabling the company to respond more flexibly to demand in global markets.
“With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years," Lisa Graver, CEO of Alvotech, said.
"Our collaboration with Lotte Biologics will bring additional manufacturing capacity in New York to support patients worldwide, complementing our existing capabilities as we scale our portfolio and prepare for future launches.”
hwkan@heraldcorp.com
